Table 2.
Subgroup analysis of efficacy effect sizes (e.g., change from baseline in HbA1c, proportion of patient with HbA1c >7% who had HbA1c <7% and change from baseline in FPG) according to concomitant therapy of EMPA on type 2 diabetes mellitus.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.